Last update 01 Nov 2024

Adalimumab biosimilar(Coherus BioSciences, Inc.)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
ADALIMUMAB-AQVH, Adalimumab biosimilar
+ [1]
Target
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Uveitis
US
13 Sep 2023
Uveitis
US
13 Sep 2023
Hidradenitis Suppurativa
US
31 Mar 2023
Hidradenitis Suppurativa
US
31 Mar 2023
Ankylosing Spondylitis
US
17 Dec 2021
Ankylosing Spondylitis
US
17 Dec 2021
Arthritis, Psoriatic
US
17 Dec 2021
Arthritis, Psoriatic
US
17 Dec 2021
Colitis, Ulcerative
US
17 Dec 2021
Colitis, Ulcerative
US
17 Dec 2021
Crohn Disease
US
17 Dec 2021
Crohn Disease
US
17 Dec 2021
Juvenile Idiopathic Arthritis
US
17 Dec 2021
Juvenile Idiopathic Arthritis
US
17 Dec 2021
Plaque psoriasis
US
17 Dec 2021
Plaque psoriasis
US
17 Dec 2021
Rheumatoid Arthritis
US
17 Dec 2021
Rheumatoid Arthritis
US
17 Dec 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Plaque psoriasisDiscovery
CA
01 Aug 2015
Plaque psoriasisDiscovery
LV
01 Aug 2015
Plaque psoriasisDiscovery
PL
01 Aug 2015
Plaque psoriasisDiscovery
UA
01 Aug 2015
Plaque psoriasisDiscovery
GE
01 Aug 2015
Plaque psoriasisDiscovery
HR
01 Aug 2015
Plaque psoriasisDiscovery
ZA
01 Aug 2015
Plaque psoriasisDiscovery
SK
01 Aug 2015
Plaque psoriasisDiscovery
IT
01 Aug 2015
Plaque psoriasisDiscovery
MD
01 Aug 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
545
ymzdnfpwmq(amgrfnbxyt) = mkgcwrydjs miyqqbtdsx (rrfixkjrgb )
Positive
14 Nov 2022
Adalimumab
ymzdnfpwmq(amgrfnbxyt) = tooxfjbzfn miyqqbtdsx (rrfixkjrgb )
Phase 3
545
(Humira (Adalimumab))
goeebxjjyw(cetwavtqxr) = ratninvqui ikvksmmmee (zcljqddgbr, fxcupkyuof - weglewmdhz)
-
18 Oct 2019
(CHS-1420)
goeebxjjyw(cetwavtqxr) = iquzvgocdr ikvksmmmee (zcljqddgbr, awmycgefdb - atqismeogf)
Phase 3
545
(tzslfqcvqz) = ddosifhasq jghuullvdf (aygqsmogfc )
Positive
14 Jun 2017
(tzslfqcvqz) = ueausqknfy jghuullvdf (aygqsmogfc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free